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Abstract
CALHM1 is a plasma membrane voltage-gated Ca2+-permeable ion channel that controls amyloid-b (Ab) metabolism and is
potentially involved in the onset of Alzheimer’s disease (AD). Recently, Rubio-Moscardo et al. (PLoS One (2013) 8: e74203)
reported the identification of two CALHM1 variants, G330D and R154H, in early-onset AD (EOAD) patients. The authors
provided evidence that these two human variants were rare and resulted in a complete loss of CALHM1 function. Recent
publicly available large-scale exome sequencing data confirmed that R154H is a rare CALHM1 variant (minor allele frequency
(MAF) = 0.015%), but that G330D is not (MAF = 3.5% in an African American cohort). Here, we show that both CALHM1
variants exhibited gating and permeation properties indistinguishable from wild-type CALHM1 when expressed in Xenopus
oocytes. While there was also no effect of the G330D mutation on Ca2+ uptake by CALHM1 in transfected mammalian cells,
the R154H mutation was associated with defects in the control by CALHM1 of both Ca2+ uptake and Ab levels in this cell
system. Together, our data show that the frequent CALHM1 G330D variant has no obvious functional consequences and is
therefore unlikely to contribute to EOAD. Our data also demonstrate that the rare R154H variant interferes with CALHM1
control of cytosolic Ca2+ and Ab accumulation. While these results strengthen the notion that CALHM1 influences Ab
metabolism, further investigation will be required to determine whether CALHM1 R154H, or other natural variants in
CALHM1, is/are associated with EOAD.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder leading to the most common form of dementia in elderly
people. Histological studies of the AD brain have revealed
pathological changes triggered by two classical lesions, the senile
plaques and neurofibrillary tangles [1,2]. Senile plaques result
from the accumulation of amyloid-b (Ab), a series of peptides
produced by sequential endoproteolysis of the amyloid precursor
protein (APP) by b- and c-secretases [3,4]. APP is genetically
linked to early-onset familial forms of AD and Ab is considered to
be a causative factor in AD [5]. The etiology of AD is influenced
by a strong genetic heterogeneity. Rare autosomal dominant
mutations cause early-onset familial AD, whereas complex
interactions between different genetic variants and environmental
factors modulate the risk for the vast majority of late-onset AD
cases [6–8].
Calcium homeostasis modulator 1 (CALHM1) [9] was identified
by a tissue-specific gene expression profiling approach [10,11] that
screened for genes located on susceptibility loci for AD and that
are preferentially expressed in the hippocampus, a brain region
affected early in AD [12]. CALHM1 is a plasma membrane Ca2+-
permeable ion channel regulated by voltage and extracellular Ca2+
(Ca2+o) levels [9,13–15]. The exact function of CALHM1 in the
brain is not completely understood, but recent evidence has
revealed that CALHM1 controls neuronal intracellular Ca2+
(Ca2+i) homeostasis and signaling, as well as Ca
2+-dependent
neuronal excitability [13,14].
We initially proposed that the naturally occurring P86L variant
in CALHM1 (rs2986017) was associated in European cohorts with
both AD risk and an earlier age-at-onset of AD [9]. Reports of
both refutation and confirmation of the association with AD risk in
independent genetic studies followed the original results [16]. A
meta-analysis of all published studies has now shown that
CALHM1 per se has no significant impact on AD risk and is
thus likely not a robust independent risk gene for AD [16].
However, the meta-analysis confirmed the association of
CALHM1 with AD age-at-onset [16]. In support of the idea that
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CALHM1 might be involved in the pathological process of AD,
we have reported that CALHM1 activation triggers a Ca2+-
dependent pathway that suppresses extracellular Ab accumulation
in cell lines [9]. Moreover, two independent genetic studies have
showed that the CALHM1 P86L variant influences Ab levels in
human cerebrospinal fluid [17,18], but see also [19]. In vitro
functional studies further demonstrated that the P86L variant –
through a mechanism yet to be determined [14] – caused a partial
loss of function by inhibiting the effect of CALHM1 on Ca2+ influx
and Ab repression [9,13,14,20,21]. Altogether these results
support the notion that CALHM1 controls Ab metabolism and
AD pathogenesis.
In a recent study [20], Rubio-Moscardo et al. reported the
identification of two natural variants in CALHM1 that occurred in
early-onset AD (EOAD) patients. The two CALHM1 variants,
G330D and R154H, were identified by sequencing CALHM1
coding regions in three independent series comprising a total of
284 EOAD patients and 326 controls. The authors found that the
G330D and R154H variants were associated with a complete loss
of CALHM1 control of Ca2+ influx in cell lines, suggesting that
these variations interfere with CALHM1 function and may thus
contribute to the risk of EOAD [20]. In the current study, we have
reassessed the functionality of the CALHM1 G330D and R154H
variants on channel gating and Ca2+ permeability by using
electrophysiological recordings and Ca2+i measurements in
CALHM1-expressing oocytes and mammalian cells, respectively.
While there was no effect of the G330D mutation on CALHM1
function in any of our experimental approaches, we found that the
R154H mutation resulted in a partial inhibition of CALHM1-
dependent Ca2+ uptake in cell lines.
In the context of characterizing CALHM1 function, Rubio-
Moscardo et al. failed to observe an inhibition of Ab accumulation
by CALHM1 expression using a modified version of the originally
described protocol of CALHM1 activation (hereafter referred to as
the ‘‘Ca2+ add-back’’ protocol [9]), which consists of transiently
lowering Ca2+o and then adding it back at physiological
concentration [13,14,21,22]. Here, we have also reassessed the
effect of CALHM1 activation on Ab levels in cell lines by testing
different Ca2+ add-back protocols, including the modified version
used by Rubio-Moscardo et al. In all conditions, we confirmed the
robust and sustained repressing effect of CALHM1 activation on
Ab accumulation. In line with the effect of the two CALHM1
variants on CALHM1-mediated Ca2+ influx, we further demon-
strate that the G330D variant has no functional effect on the
control of Ab levels by CALHM1, whereas the R154H variant is
associated with a partial loss of CALHM1 function.
Results and Discussion
CALHM1 variant frequency in a large-scale exome
sequencing database
We interrogated the NHLBI Exome Sequencing Project (ESP)
database to determine the frequency of the CALHM1 R154H and
G330D variants (see Methods). The R154H variant
(10:105218048, rs371900329) was found in a single individual
across the entire ESP cohort (minor allele frequency (MAF)
= 0.015%). In contrast, the G330D variation (10:105215071,
rs114015468) was found in one individual of European-American
ethnicity and in 151/4,255 individuals of African-American
ethnicity (a 3.55% MAF in the latter population). Therefore,
sequencing analysis of these large human cohorts show that
CALHM1 R154H is a rare variation, but that CALHM1 G330D,
with a MAF above 1%, is not.
The R154H and G330D variants do not alter CALHM1
gating or Ca2+ permeability
Heterologously expressed CALHM1 exhibits properties consis-
tent with it being a Ca2+-permeable ion channel regulated by
voltage and Ca2+o [14,15]. Rubio-Moscardo et al. observed that
the R154H and G330D variants resulted in a complete loss of
CALHM1-dependent Ca2+ influx in transfected mammalian cells
[20]. To determine if R154H or G330D alters CALHM1 gating
or Ca2+ permeability, we recorded whole cell currents from
Xenopus oocytes injected with wild-type (WT)-CALHM1, R154H-
CALHM1, and G330D-CALHM1 cRNA. In the presence of
2 mM Ca2+o, membrane depolarization of oocytes expressing
WT-CALHM1 or the CALHM1 variants resulted in slowly-
activating outward currents that deactivated upon stepping to
hyperpolarized voltages (Figs. 1A–C). Using the same conditions,
similar currents were not observed in water-injected oocytes (data
not shown, see also Ref. [14]). This indicates that R154H-
CALHM1 and G330-CALHM1 form functional voltage-depen-
dent channels.
Lowering Ca2+o resulted in a left shift in the apparent
conductance-voltage (G-V) relationship for CALHM1, allowing
channels to open at resting membrane potentials (Fig. 1D, see also
Ref. [14]). To determine if R154H-CALHM1 and G330-
CALHM1 are also regulated by Ca2+o, we recorded currents
from CALHM1-expressing oocytes in divalent-free and 2 mM
Ca2+o containing solutions, and analyzed the apparent G-V
relationships. For WT-CALHM1, 2 mM Ca2+o right shifted the
apparent G-V relationship by 136.7 mV from a half-activation
voltage (V0.5) of –75.9 mV in 0 mM Ca
2+
o to +60.8 mV in 2 mM
Ca2+o (Fig. 1D). Similarly, the presence of 2 mM Ca
2+
o caused
145.2 mV and 141.6 mV right shifts in the apparent G-V
relationships for R154H-CALHM1 and G330D-CALHM1,
respectively (Fig. 1D). These results suggest that R154H-
CALHM1 and G330D-CALHM1 are regulated by both voltage
and Ca2+o, with gating properties indistinguishable from WT-
CALHM1.
We then asked whether the lack of Ca2+ influx observed by
Rubio-Moscardo et al. in cell lines expressing R154H-CALHM1
and G330D-CALHM1 was due to alterations in Ca2+ permeabil-
ity. To assess if R154H-CALHM1 and G330D-CALHM1 are
permeable to Ca2+, we measured reversal potentials (Erev) in
solutions containing 0 or 2 mM Ca2+o with constant NaCl. The
presence of Ca2+o resulted in a shift in Erev to more depolarized
voltages for WT-CALHM1, R154H-CALHM1, and G330D-
CALHM1 (Fig. 1E). This shift in Erev was not significantly
different for the two variants compared to WT-CALHM1,
suggesting that relative Ca2+ permeability was not altered. In
conclusion, we were unable to detect any difference in the gating
or Ca2+ permeability for the R154H and G330D variants,
compared to WT-CALHM1.
Effect of the CALHM1 G330D and R154H variants on Ca2+
influx in mammalian cells
To further investigate the effect of the G330D and R154H
mutations on CALHM1 function, we evaluated CALHM1-
mediated Ca2+ influx by measuring Ca2+i levels in transfected
hippocampal HT-22 cells loaded with the fluorescent Ca2+
indicator Fluo-4. Removal and subsequent add-back of Ca2+o
results in a CALHM1-mediated increase in Ca2+i levels [9]. Upon
Ca2+ add-back stimulation, we found that G330D-CALHM1
produced the same elevation in Ca2+i levels as WT-CALHM1
(Figs. 2A and 2B). In contrast, R154H significantly inhibited
CALHM1-mediated Ca2+ influx in these conditions (Figs. 2A and
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2B). R154H-CALHM1 only exhibited a partial loss of function
compared to the dead mutant W114A-CALHM1 that, as expected
[13], fully inhibited CALHM1-mediated Ca2+ influx (Figs. 2A and
2B). These results show that the G330D mutation did not alter
CALHM1 function, while the R154H mutation resulted in a
partial loss of function in mammalian cells.
Reevaluation of the effect of CALHM1 activation on Ab
levels
In our original study [9], we showed that Ca2+ add-back in two
CALHM1 expressing neuroblastoma cell lines had an inhibitory
effect on extracellular Ab accumulation. Expression of CALHM1
in N2a cells decreased Ab levels, while silencing of CALHM1 in
SH-SY5Y cells increased Ab levels, upon Ca2+ add-back [9]. The
decrease in Ab levels observed in CALHM1-transfected cells was
accompanied by enhanced secretion of sAPPa [9], the product of
the non-amyloidogenic processing of APP [23]. In the context of
characterizing the functionality of the identified CALHM1
variants, Rubio-Moscardo et al. failed to observe any effect of
CALHM1 expression on extracellular Ab accumulation [20]. The
authors tested CALHM1-transfected HEK293 cells and used a
modified version of the original Ca2+ add-back protocol, which
extended the Ca2+ omission step to 30 min [20], compared to 1–
10 min in the previous studies [9,13,14,21,22]. A more significant
difference in Rubio-Moscardo et al. protocol relates to the Ab
secretion time period after Ca2+ add-back: 6 hr [20] vs. 60 min in
our protocol [9]. In addition, Rubio-Moscardo et al. performed
the Ca2+ add-back protocol in the presence of 1% FBS, an
ingredient that was omitted in our previous study.
In this context, we reassessed the effect of CALHM1 expression
on Ab levels not only in N2a cells, but also in HEK293 cells, and
by using Ca2+ add-back conditions that included: (i) a 30 min Ca2+
omission, (ii) 1% FBS, and (iii) Ca2+ add-back secretion time
periods that extended to 6 hr. In all tested conditions, Ca2+ add-
back in CALHM1 expressing cells consistently inhibited the
accumulation of extracellular Ab (Fig. 3). Specifically, the amount
of time allowed for secretion following Ca2+ add-back (Figs. 3A
and 3C) and the presence of 1% FBS (Figs. 3B and 3D) did not
affect CALHM1-mediated inhibition of Ab accumulation. In
addition, the previously reported CALHM1-mediated stimulation
of sAPPa release [9] was observed in nearly all tested conditions
(Fig. 3), with the exception of the N2a cells incubated without FBS
(for the 6 hr secretion time point, see Fig. 3A) and at all time
points with FBS present (Fig. 3B). These data show that, in
different cell lines, CALHM1 expression and its activation by the
Ca2+ add-back condition generate a potent and long-lasting
repressing effect on extracellular Ab accumulation. The differenc-
es in the Ca2+ add-back protocol used by Rubio-Moscardo et al.
Figure 1. Effect of the R154H and G330D variants on CALHM1 gating and Ca2+ permeability. A–C. Currents observed in oocytes
expressing (A) WT-CALHM1, (B) G330D-CALHM1, and (C) R154H-CALHM1 in standard bath solution containing 2 mM Ca2+o in response to voltage
pulses from280 mV to +60 mV; holding potential240 mV. D. Following a series of voltage pulses, currents at280 mV were measured to determine
G-V relations in the presence and absence of Ca2+o. For each oocyte, Gmax was determined by fitting 0 mM Ca
2+
o data with a Boltzmann function; all
currents were then normalized to Gmax. Normalized data were fit with Boltzmann functions with the assumption that Ca
2+ does not affect Gmax
[14,15]. WT-CALHM1 0 mM Ca2+o (red circles) V0.5 = 275.9 mV; R154H-CALHM1 0 mM Ca
2+
o (blue circles) V0.5 = 282.8 mV; G330D-CALHM1 0 mM
Ca2+o (black circles) V0.5 = 278.8 mV; WT-CALHM1 2 mM Ca
2+
o (red triangles) V0.5 = 60.8 mV; R154H-CALHM1 2 mM Ca
2+
o (blue triangles)
V0.5 = 62.4 mV; G330D-CALHM1 2 mM Ca
2+
o (black triangles) V0.5 = 62.8 mV. E. Changes in Erev resulting from changing from 0 to 2 mM Ca
2+
o solution
in oocytes expressing WT-CALHM1 (red), G330D-CALHM1 (black), and R154H-CALHM1 (blue). n = 4–6 oocytes for each condition; Error bars, SE.
doi:10.1371/journal.pone.0112484.g001
Effect of CALHM1 Human Variants on Cytosolic Ca2+ and Ab Levels
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e112484
can therefore not explain the disparity in the results observed their
study [20]. We note that all transfections performed by Rubio-
Moscardo et al. did not include assessment of protein expression
efficiency after transfection, raising concerns about the functional
expression of CALHM1 in their system. Indeed, Ca2+ measure-
ments are very sensitive and could have detected low CALHM1
expression (e.g., in the presence of poor transfection efficiency) that
would fail to translate into an effect on Ab levels.
Effect of the CALHM1 G330D and R154H variants on Ab
levels
To determine whether the R154H and G330D variants affect Ab
accumulation, we exposed transfected N2a cells to the 1 hr Ca2+
add-back protocol, as in Fig. 3A. We observed that G330D-
CALHM1 produced the same inhibitory effect on Ab accumulation
as WT-CALHM1 (Figs. 4A and 4B). In contrast, expression of
R154H-CALHM1 was less effective in reducing Ab levels,
compared to WT-CALHM1 (Figs. 4A and 4B). In addition,
WT-CALHM1 and G330D-CALHM1 produced comparable
stimulation of sAPPa secretion, while there was less sAPPa
secreted from cells expressing R154H-CALHM1 (Fig. 4A).
These effects on APP metabolism did not result from significant
changes in the expression levels of the different CALHM1
mutants (Fig. 4A). These data, which are in line with the effect
of the two CALHM1 variants on CALHM1-mediated Ca2+
influx in mammalian cells (Fig. 2), further demonstrate that the
G330D variant has no obvious functional effect on CALHM1,
whereas the R154H variant is associated with a partial loss of
CALHM1 function.
Previous work has shown that Ca2+i disturbances can affect APP
processing and Ab production [24,25]. Notably, expression of
BACE1 b-secretase is controlled by different Ca2+-dependent
transcriptional pathways [26,27]. To determine whether
CALHM1-mediated Ca2+ influx influences BACE1 expression,
Figure 2. Effect of the CALHM1 G330D and R154H variants on
Ca2+ influx in mammalian cells. A. Ca2+i measurements with Fluo-4
loading and Ca2+ add-back in HT-22 cells transiently transfected with
WT-, G330D-, R154H-, and W114A-CALHM1 or empty vector. Cells were
incubated in Ca2+-free buffer (0 CaCl2) for 30 min, and then challenged
with physiological Ca2+o concentration (1.4 mM CaCl2) to monitor the
restoration of Ca2+i levels. RFU, relative fluorescence units. B. Peak of
Ca2+i concentration measurements after Ca
2+ add-back expressed as
DF/F0. Error bars, SEM. *P,0.01, **P,0.001, relative to vector-
transfected cells; #P,0.01, ##P,0.001, relative to WT-CALHM1-
transfected cells (ANOVA with Bonferroni correction, n = 3 independent
experiments as in (A)).
doi:10.1371/journal.pone.0112484.g002
Figure 3. Effect of CALHM1 activation on Ab levels. A–D. APP-
N2a (A and B) and APP-HEK293 (C and D) cells transfected with empty
vector or WT-CALHM1 were subjected to Ca2+ add-back conditions in
the absence (CaAB, A and C) or presence of 1% FBS (CaAB 1% FBS, B
and D). Extracellular Ab and sAPPa were analyzed by WB after the
indicated periods of secretion. Cell lysates were probed using anti-Myc
and anti-actin antibodies to detect CALHM1 and actin, respectively.
doi:10.1371/journal.pone.0112484.g003
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we measured BACE1 levels by western blotting (WB) in cells
transfected with WT or mutated CALHM1. No significant
differences in BACE1 levels were observed in these conditions
(Fig. 4A), showing that CALHM1 did not affect Ca2+-dependent
BACE1 expression. Therefore, CALHM1 influenced Ab levels by
a mechanism independent of BACE1 transcriptional control.
Together our data show that, while R154H-CALHM1
exhibits normal channel properties at the plasma membrane
(Fig. 1), it impairs the overall control by CALHM1 of Ca2+ cell
uptake (Fig. 2) and APP metabolism (Figs. 3 and 4). These
results suggest that R154H does not prevent the formation of a
fully functional channel, but instead may act by interfering with
CALHM1 trafficking and/or its maturation to reduce the
expression levels or stability of CALHM1 at the plasma
membrane. The effect of R154H on CALHM1-mediated Ca2+
influx could also indirectly be influenced by other plasma
membrane Ca2+ channels, such the store-operated Ca2+ (SOC)
channels. Our previous work has failed, however, to observe an
effect of CALHM1 activation on SOC entry [14] and SOC
channel inhibition did not interfere with CALHM1-mediated
Ca2+ influx [9]. Selective blockage of other common plasma
membrane Ca2+ channels in excitable cells, such as the voltage-
gated Ca2+ channels (VGCCs), was also without effect on
CALHM1-mediated Ca2+ influx [9]. Collectively, these data
suggest that CALHM1 does not influence SOC channels or
VGCCs. The effect of the CALHM1 R154H mutation is thus
unlikely to be due to defects in the response of these other
channels. Nevertheless, we cannot exclude the possibility at this
point that other unidentified pathways of Ca2+ re-entry might
be involved in this mechanism. The effect of the R154H
mutation on CALHM1 is therefore likely to be complex and
further investigation will be required to determine the precise
mechanisms whereby this mutation interferes with CALHM1
function.
Conclusions
In the present work, we used electrophysiology and cell biology
approaches to show that: (i) CALHM1 G330D is a frequent
variant with no functional consequences on CALHM1 channel
properties and is therefore unlikely to contribute to the risk of
EOAD; and (ii) CALHM1 R154H is a rare variant that causes a
partial loss of CALHM1 function and increases Ab levels in cell
lines. These results motivate further investigation aimed at
determining whether CALHM1 R154H, or other functional
natural variants in CALHM1, is/are associated with EOAD.
Materials and Methods
Antibodies and plasmids
Anti-myc antibody (71D01) was from Cell Signaling Technol-
ogy, anti-actin antibody from BD Transduction Laboratories, anti-
Ab1–17 (6E10) antibody from Covance, and anti-BACE1 antibody
from Abcam. Myc-tagged WT- and W114A-CALHM1 in
pcDNA3.1 vectors, as well as WT-CALHM1 in the pBF oocyte
expression vector, were described previously [9,13]. G330D- and
R154H-CALHM1 were created using Quickchange II site-
directed mutagenesis kit (Agilent Technologies) and confirmed
by sequencing.
Cell lines and transfections
The cell lines used in this study were described previously
[13,23]. HT-22 cells were kindly provided by Dr. D. Schubert
(Salk Institute, La Jolla, CA). HEK293 cells stably transfected with
human APP695 (APP-HEK293) were provided by Dr. Luciano
D’Adamio (Albert Einstein College of Medicine, Bronx, NY). N2a
cells stably transfected with human APP695 (APP-N2a) were
obtained from Dr. Gopal Thinakaran (university of Chicago,
Chicago, IL). HT-22 and APP-HEK293 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS, HyClone, Thermo Fisher Scientific
Inc.), 2 mM L-glutamine, and penicillin/streptomycin (Life
Technologies) at 37uC under 5% CO2. APP-N2a cells were
maintained in DMEM/Opti-MEM (1:1) supplemented with 10%
FBS, 2 mM L-glutamine, and penicillin/streptomycin at 37uC
under 5% CO2. Cells were transiently transfected with CALHM1
cDNAs using Lipofectamine 2000, as per the manufacturer’s
instructions (Life Technologies). Transfections were performed in
complete culture medium for APP-N2a and APP-HEK293 cells,
or in Opti-MEM for HT-22 cells. For HT-22 cells, Opti-MEM
was replaced 5 hr post-transfection with complete culture medi-
um. All cell lines were processed 24 hr after transfection.
Ca2+ add-back assay
Ca2+ add-back was performed as described previously [9,13],
with the following modifications: Cells were incubated for 30 min
in Ca2+/Mg2+-free Hank’s balanced salt solution (HBSS) supple-
mented with 20 mM HEPES buffer, 0.5 mM MgCl2, and 0.4 mM
MgSO4. Ca
2+ was then added back for the indicated periods of
time to a final concentration of 1.4 mM in the absence or presence
of 1% FBS.
Intracellular Ca2+ measurements
Ca2+i levels were measured using Fluo-4 (Fluo-4 NW Ca
2+
Assay kit, Life Technologies) as described previously [9,13].
Briefly, HT-22 cells were transfected with WT-CALHM1,
CALHM1 mutants, or empty vector, as described above.
Twenty-four hours post-transfection, cells were loaded with
Fluo-4 and fluorescence measurements were performed at room
Figure 4. Effect of the CALHM1 G330D and R154H variants on
Ab levels. A. APP-N2a cells were transiently transfected with empty
vector or WT-, G330D-, and R154H-CALHM1, as well as W114A-CALHM1
(CALHM1 dead mutant control, see Ref. [13]). Cells were then subjected
to Ca2+ add-back as in Fig. 3A. Extracellular Ab and sAPPa were
analyzed by WB after 1 hr of secretion. Cell lysates were probed using
anti-Myc, anti-BACE1, and anti-actin antibodies to detect CALHM1,
BACE1, and actin, respectively. B. Densitometric analyses and quanti-
fication of Ab levels in 3 independent measurements as in (A). Error
bars, SEM; *P,0.01, **P,0.001, relative to vector-transfected cells; #P,
0.05, ##P,0.001, relative to WT-CALHM1-transfected cells (ANOVA with
Bonferroni correction).
doi:10.1371/journal.pone.0112484.g004
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temperature with a Tecan Genius Pro plate reader at 480 nm
excitation and 535 nm emission. After fluorescence measure-
ments, cells were washed and analyzed by WB to analyze
CALHM1 protein levels.
WB analyses
Cell extracts (5–20 mg, depending on the primary antibody
used) were analyzed by SDS-PAGE using the antibodies listed
above. Secreted total Ab and sAPPa levels were analyzed by WB,
as described previously [28,29]. Briefly, 20 mL of medium was
electrophoresed on 16.5% Tris-tricine gels (for Ab WB) or 10%
Tris-HCl gels (sAPPa WB) and then transferred onto nitrocellulose
membranes. For Ab WB, membranes were microwaved for 5 min
in PBS. Membranes were then blocked in 5% fat-free milk in TBS
and incubated overnight at 4uC with 6E10 antibody (1:1000 in
SuperBlock Blocking Buffer, Thermo Fisher Scientific). A standard
ECL detection procedure was then used.
Electrophysiology in Xenopus oocytes
All procedures involving the use of Xenopus laevis were
approved by the University of Pennsylvania Institutional Animal
Care and Use Committee. Adult female Xenopus laevis obtained
from Xenopus One were maintained in existing university
facilities. To obtain oocytes, Xenopus laevis were first anaesthe-
tized by immersion in 0.15% tricaine for 15 minutes. Once
anaesthetized, frogs were placed supine, a 1.0 cm incision was
made in the lower abdominal quadrant through which part of an
ovary was raised and removed and then the incision was closed
with 4–0 Reli sutures (MYCO Medical). Oocytes were defollicu-
lated with type 2 collagenase (Worthington Biochemical). No
Xenopus laevis frogs or embryos were sacrificed for this study.
CALHM1 cRNAs were synthesized from MluI-linearized
plasmids with SP6 RNA polymerase (mMessage mMachine kit,
Ambion). CALHM1 cRNA (2 ng) was injected into stage IV–VI
Xenopus laevis oocytes with Xenopus connexin-38 antisense
oligonucleotide (ASO; 80 ng). Injected oocytes were incubated
for 1 day at 16uC in ND96 medium (96 mM NaCl, 2 mM KCl,
1.8 mM CaCl2, 1 mM MgCl2, 2.5 mM Na-pyruvate, 1X penicil-
lin-streptomycin, pH 7.6) and then injected with 50 nl of a 20 mM
BAPTA, 10 mM Ca2+ solution at least 30 min before recording to
prevent activation of endogenous Ca2+-activated Cl2 currents.
Data were acquired at 1 kHz using an OC-725C amplifier
(Warner Instrument Corp.) with a 16-bit A/D converter
(Instrutech ITC-16). Electrodes were made with TW100F-6 glass
(World Precision Instruments, Inc.) using a model P-87 Sutter
Instrument Co. micropipette puller and then filled with 3 M KCl.
Standard bath solutions (pH 7.2) contained (in mM) 100 Na+,
100 Cl2, 2 K+, and 10 HEPES with 2 Ca2+ or 0.5 EGTA and 0.5
EDTA to create the divalent cation-free solution. To determine
conductance-voltage relations in the presence and absence of
Ca2+o, currents at 280 mV were measured following a series of
voltage pulses, as described before [14,15]. For the permeability
experiments, standard bath solution (pH 7.2) contained (in mM)
17 Na+, 10 Cl2 62 Ca2+. Instantaneous I–V recordings were
analyzed to determine the reversal potential, as described before
[14,15]. Recordings were analyzed with Igor Pro.
Variation allele frequency analysis
We interrogated the NHLBI Exome Sequencing Project (ESP)
release ESP6500SI-V2 using the Exome Variant Server [30]. The
ESP measured genotypes in a population of 6,503 individuals
across several cohorts using an exome-sequencing assay. Exome
sequencing makes it possible to observe genomic sequence over the
covered exonic regions and to call rare variants in these regions.
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